APSR2026-960

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP08-018
P73
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1288/0bdc82184134c6c8d68edbaf958b89cc.pdf
Format: PDF Only
06. Tuberculosis
9

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Ksenia Rudakova - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Roman Ladyu - National Medical Research Center for Phthisiopulmonology and Infectious Diseases, Ministry of Health of the Russian Federation, Moscow, Russian Federation Not applicable Moscow Russian Federation
Anastasia Gaida * National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Eduard Vaniev - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Olga Kuteinikova - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Valentina Tinkova - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Galina Mozhokina - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Anastasia Samoilova - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
Irina Vasilyeva - National Medical Research Center for Phthisiopulmonology and Infectious Diseases Not applicable Moscow Russian Federation
-
-
-
-
-
-
Presenting Author Details
Anastasia
Gaida
nsovca@yandex.ru
+7+7+7+79992991986
31-40
 
Original Research
Effect of linezolid dose and patient body weight on the development of neurotoxic reactions during multidrug-resistant tuberculosis therapy
Maximum 25 words
Abstract Content
Linezolid is effective in drug-resistant tuberculosis, but neurotoxic adverse events may interrupt treatment. This study assessed factors associated with neurotoxic reactions during linezolid therapy in patients with drug-resistant tuberculosis.
A retrospective descriptive analysis included 42 patients receiving linezolid-containing regimens for multidrug-resistant or pre-extensively drug-resistant tuberculosis in 2023-2024. All had registered neurotoxic adverse events. Demographics, body weight, linezolid dose, time to adverse event registration and discontinuation were obtained from medical records. Data are presented as mean, median, range, numbers and percentages. Fisher’s exact test was used.
Among 42 patients, 26 were women (61.9%); mean age was 45.9±12.6 years and mean body weight 61.9±14.0 kg. All received linezolid 600 mg/day; mean weight-adjusted dose was 9.88±2.53 mg/kg/day. Linezolid discontinuation due to drug-induced polyneuropathy occurred in 61.9% (26/42). Mean time to adverse event diagnosis was 43.07 weeks and to discontinuation 55.8 weeks. In patients >60 kg receiving ≤10.0 mg/kg/day, symptoms appeared after 33.6±27.5 weeks, median 26.1, and discontinuation occurred in 45.5% (10/22). In patients 50-60 kg receiving 10.1-12.0 mg/kg/day, symptoms appeared after 33.5±24.6 weeks, median 28.4, and discontinuation occurred in 80.0% (12/15). In patients <50 kg receiving >12.0 mg/kg/day, symptoms appeared after 32.6±20.5 weeks, median 28.4, and discontinuation occurred in 80.0% (4/5). In patients ≤60 kg, relative daily dose exceeded 10 mg/kg/day and discontinuation was more frequent than in patients >60 kg: 80.0% versus 45.5%, p=0.029. Median cumulative dose was 169.2 g versus 214.2 g, respectively.
A higher linezolid dose (>10 mg/kg/day), associated with lower body weight in patients receiving 600 mg/day, was significantly associated with discontinuation due to adverse events manifesting as peripheral neuritis. Dose optimization by body weight may improve tolerability.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Tuberculosis, Linezolid, Neurotoxicity
maximum 3 keywords and no abbreviations, separated by commas
The authors declare no conflict of interest.
325